Skip to content

EBITDA at other companies

CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-$19.64M-187%
Immunome logo
ImmunomeIMNM
-$58.73M-33.4%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$116.05M-23.8%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$104.01M-10.1%
uniQure logo
uniQureQURE
-$42.76M-22.9%
Eli Lilly logo
Eli LillyLLY

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$28.3M-29.5%
Net income-$26.2M-44.1%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Cash & equivalents$54.0M+21.5%
Total debt$4.2M+10.9%
Total equity$347.4M+22.1%
Total assets$410.8M+24.7%

Cash flow

See full
Operating cash flow-$31.5M-45.8%
CapEx$6.9M+47.3%
Free cash flow-$38.3M-46.1%

Valuation

See full
Market cap$342.14M+33.2%
Enterprise value$292.34M+35.2%
P/S34.2×+19.6×

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp
FCF margin-1,073.3%

Returns & leverage

See full
Return on equity-35.2%+2.3pp
Debt / equity0.0×
Current ratio8.7×-8.3×

Where this comes from

Calculated from Perspective Therapeutics’s reported figures.

$28.3Mebit+
$1.1MDepreciation Depletion & Amortization
=-$27.16M

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perspective Therapeutics's EBITDA?
Perspective Therapeutics (CATX) reported EBITDA of -$27.16M in Q1 2026.
How has Perspective Therapeutics's EBITDA changed year-over-year?
Perspective Therapeutics's EBITDA decreased by 28.7% year-over-year, from -$21.1M to -$27.16M.
What is the long-term trend for Perspective Therapeutics's EBITDA?
Over 2 years (2023 to 2025), Perspective Therapeutics's EBITDA has grown at a 66.2% compound annual growth rate (CAGR), from -$39.96M to -$110.31M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.